<DOC>
	<DOCNO>NCT00849680</DOCNO>
	<brief_summary>The goal study understand safety , tolerability immunogenicity Merck Trivalent Adenovirus Serotype 5 HIV-1 gag/pol/nef Vaccine ( MRKAd 5 HIV-1 gag/pol/nef ) vaccine healthy human volunteer compare placebo . The study also evaluate number dose level necessity timing booster injection .</brief_summary>
	<brief_title>A Study Safety , Tolerability , Immunogenicity MRKAd5 Gag/Pol/Nef Vaccine Healthy Adults ( V520-016 )</brief_title>
	<detailed_description>The study proceed four stage . Following stage I , II III , subject Postdose 1 ( PD1 ) clinical laboratory safety data review Safety Evaluation Committee ( SEC ) . If data acceptable , next stage initiate . - In Stage I , participant randomize receive 3 dos 3x10^9vp/dose level Trivalent vaccine placebo . - In Stage II , participant randomize receive 2 3 dos 3x10^10vp/dose level Trivalent vaccine placebo . - In Stage III , participant randomize receive 3 dos Trivalent vaccine titer 1x10^11vp/dose , 3x10^6vp/dose , 3x10^7vp/dose , 3x10^8vp/dose placebo . - In Stage IV , participant randomize treatment group . In addition , participant randomize MRKAd 5 HIV-1 gag Monovalent vaccine . In stage , participant pre-stratified baseline Ad5 titer ( = &lt; 200 , &gt; 200 ) , ensure even distribution participant high low Ad5 titer across various treatment group .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects 18 Years 45 Years Stages IIII 18 Years 50 Years Stage IV . Subject good general health Subjects reproductive potential agree use acceptable method birth control study Subject test negative Hepatitis B , Hepatitis C , HIV Subject recent history fever time vaccination Subject receive immune globulin blood product 3 month prior injection Subject vaccinate live virus vaccine 30 day prior receipt first dose Subject vaccinate inactivated vaccine 14 day prior receipt first dose Subject chronic medical condition consider progressive Subject history malignancy Subject weigh less 105 lb . Female subject pregnant breast feeding , Male subject plan impregnate first year study Subject contraindication intramuscular injection Subject tattoo deltoid region arm injection DepoProvera Subject unlikely unwilling adhere low risk sex practice course study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>HIV Seronegativity</keyword>
	<keyword>Preventive Vaccine</keyword>
</DOC>